Home › Companies › RECURSION PHARMACEUTICALS, INC. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 17, 2026: 4 items on RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed June 18, 2026: 2 elected · 2 approved.
Notable dissent: 2 directors (12.7%, 11.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore RECURSION PHARMACEUTICALS, INC. in the interactive database Compare manager voting policies
These tallies are RECURSION PHARMACEUTICALS, INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Najat Khan, Ph.D. | 210,437,751 | -- | -- | 27,907,256 | 126,675,762 | 88% | Elected | — |
| Elect Director: Franziska Michor, Ph.D. | 208,124,737 | -- | -- | 30,220,270 | 126,675,762 | 87% | Elected | — |
| 2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement | 206,171,008 | 30,893,147 | 1,280,852 | -- | 126,675,762 | 87% | Approved | — |
| 3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 | 361,743,500 | 2,148,771 | 1,128,498 | -- | -- | 99.4% | Approved | — |
Source: RECURSION PHARMACEUTICALS, INC., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
295 asset managers disclosed a vote on at least one RECURSION PHARMACEUTICALS, INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Najat Khan, Ph.D.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Najat Khan, Ph.D.”): 210,437,751 for, 27,907,256 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"): Proposal 1: T…”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 13,524,020 for, 1,139,490 withheld, 15,336 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,442 | 0 | 3 | 0 | For |
| State Street | 1,881,499 | 0 | 0 | 2,160 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 0 | 0 | 91,230 | Mixed |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 366,512 | 0 | 0 | 0 | For |
| FundVantage Trust | 0 | 0 | 0 | 311,293 | Withhold |
| Guggenheim | 0 | 0 | 0 | 204,222 | Withhold |
| American Century | 0 | 0 | 0 | 132,750 | Withhold |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 0 | 0 | 77,000 | Withhold |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 64,004 | Withhold |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 57,414 | Withhold |
| AuguStar | 0 | 0 | 0 | 44,555 | Withhold |
| Calvert | 0 | 0 | 0 | 37,513 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 37,311 | Withhold |
| ProShares | 0 | 0 | 0 | 35,438 | Withhold |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 28,907 | Withhold |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Franziska Michor, Ph.D.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Franziska Michor, Ph.D.”): 208,124,737 for, 30,220,270 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"): Proposal 1: T…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 13,227,070 for, 1,436,440 withheld, 15,336 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,442 | 0 | 3 | 0 | For |
| State Street | 1,881,499 | 0 | 0 | 2,160 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 0 | 0 | 91,230 | Mixed |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 69,563 | 0 | 0 | 296,949 | Mixed |
| FundVantage Trust | 0 | 0 | 0 | 311,293 | Withhold |
| Guggenheim | 0 | 0 | 0 | 204,222 | Withhold |
| American Century | 0 | 0 | 0 | 132,750 | Withhold |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 0 | 0 | 77,000 | Withhold |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 64,004 | Withhold |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 57,414 | Withhold |
| AuguStar | 0 | 0 | 0 | 44,555 | Withhold |
| Calvert | 0 | 0 | 0 | 37,513 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 37,311 | Withhold |
| ProShares | 0 | 0 | 0 | 35,438 | Withhold |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 28,907 | Withhold |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
87% Approved · of votes cast
Prior year: 98.7% for (June 18, 2025 meeting) ▼ 11.7 pts
Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement”): 206,171,008 for, 30,893,147 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of RECURSION PHARMACEUTICALS, INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, 1,570 for, 13,679,273 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,356,830 | 1,616 | 0 | 0 | For |
| State Street | 1,879,098 | 4,561 | 0 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 91,230 | 0 | 0 | Mixed |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 69,563 | 296,949 | 0 | 0 | Mixed |
| FundVantage Trust | 0 | 311,293 | 0 | 0 | Against |
| Guggenheim | 0 | 204,222 | 0 | 0 | Against |
| American Century | 0 | 132,750 | 0 | 0 | Against |
| Investment Managers Series Trust II | 102,692 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 77,000 | 0 | 0 | Against |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 64,004 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 57,414 | 0 | 0 | Against |
| AuguStar | 0 | 0 | 44,555 | 0 | Abstain |
| Calvert | 0 | 37,513 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 37,311 | 0 | 0 | Against |
| ProShares | 0 | 35,438 | 0 | 0 | Against |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
Fund voting reports, all 55 managers: 13,306,787 for, 1,431,097 against, 44,555 abstained, 1 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO LTD | 20,028,719 | 0 | 0 | 0 | For |
| MIC Capital Management UK LLP | 8,451,758 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 0 | 5,384,024 | 0 | 0 | Against |
| State Street | 5,093,926 | 39,340 | 0 | 0 | For |
| Vanguard | 4,316,134 | 18,935 | 0 | 0 | For |
| Lingotto Investment Management LLP | 4,062,729 | 0 | 0 | 0 | For |
| BlackRock | 3,614,590 | 70,780 | 0 | 0 | For |
| MARSHALL WACE, LLP | 3,064,357 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 3,034,418 | 0 | 0 | 0 | For |
| Northern Trust | 2,035,454 | 132,271 | 0 | 0 | Mixed |
| Goldman Sachs | 1,009,851 | 53,053 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 945,102 | 0 | 0 | Against |
| Man Group plc | 843,285 | 0 | 0 | 0 | For |
| CAPITAL FUND MANAGEMENT S.A. | 818,892 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 762,609 | 0 | 0 | Against |
| Vestmark Advisory Solutions, Inc. | 702,311 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 610,133 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 546,302 | 0 | 0 | Against |
| UBS | 0 | 533,148 | 0 | 0 | Against |
| AllianceBernstein | 0 | 448,204 | 0 | 0 | Against |
| Lazard | 0 | 389,686 | 0 | 0 | Against |
| Charles Schwab | 386,132 | 0 | 0 | 0 | For |
| Allianz | 0 | 340,440 | 0 | 0 | Against |
| Gotham Asset Management, LLC | 0 | 317,188 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 262,465 | 0 | 0 | 0 | For |
Institutional-manager reports, all 246 managers: 61,337,371 for, 12,316,148 against, 4,937 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026”): 361,743,500 for, 2,148,771 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 14,739,544 for, 44,555 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,445 | 0 | 0 | 0 | For |
| State Street | 1,883,659 | 0 | 0 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 461,991 | 0 | 0 | 0 | For |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 366,512 | 0 | 0 | 0 | For |
| FundVantage Trust | 311,293 | 0 | 0 | 0 | For |
| Guggenheim | 204,222 | 0 | 0 | 0 | For |
| American Century | 132,750 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 102,692 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 77,000 | 0 | 0 | 0 | For |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 64,004 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 57,414 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 44,555 | 0 | Abstain |
| Calvert | 37,513 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,311 | 0 | 0 | 0 | For |
| ProShares | 35,438 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of June 18, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 530,628,653 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.58% |
| 2 | State Street | 0.35% |
| 3 | ARK Venture Fund | 0.12% |
| 4 | BlackRock | 0.11% |
| 5 | Lincoln Financial | 0.09% |
| 6 | Fidelity | 0.08% |
| 7 | Charles Schwab | 0.07% |
| 8 | Equitable | 0.07% |
| 9 | FundVantage Trust | 0.06% |
| 10 | Guggenheim | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BAILLIE GIFFORD & CO LTD | 3.77% |
| 2 | MIC Capital Management UK LLP | 1.59% |
| 3 | Amova Asset Management Co., Ltd. | 1.01% |
| 4 | State Street | 0.97% |
| 5 | Vanguard | 0.82% |
| 6 | Lingotto Investment Management LLP | 0.77% |
| 7 | BlackRock | 0.69% |
| 8 | MARSHALL WACE, LLP | 0.58% |
| 9 | ARK Investment Management LLC | 0.57% |
| 10 | Northern Trust | 0.41% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 47,187,759 | 8.89% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 43,192,306 | 8.14% | Form 13F, quarter ended March 31, 2026 |
| ARK Investment Management LLC | 37,316,856 | 7.03% | Schedule 13G, filed February 3, 2026 |
| Vanguard Portfolio Management | 31,369,274 | 5.91% | Schedule 13G, filed July 31, 2026 |
| State Street | 28,490,638 | 5.37% | Form 13F, quarter ended March 31, 2026 |
| BAILLIE GIFFORD & CO | 23,774,972 | 4.48% | Schedule 13G, filed February 5, 2026 |
| Zachary Bogue | 13,628,602 | 2.57% | Proxy statement (DEF 14A), table as of April 21, 2026 |
| Blake Borgeson | 6,374,101 | 1.20% | Proxy statement (DEF 14A), table as of April 21, 2026 |
| Goldman Sachs | 6,065,661 | 1.14% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 5,657,578 | 1.07% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 530,628,653 shares outstanding, as reported by RECURSION PHARMACEUTICALS, INC. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At RECURSION PHARMACEUTICALS, INC.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 295 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,052 separate fund positions. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT. — RECURSION PHARMACEUTICALS, INC.'s filing reports the proposal as approved, with 87% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RECURSION PHARMACEUTICALS, INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS, INC.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
RECURSION PHARMACEUTICALS, INC. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “RECURSION PHARMACEUTICALS (RXRX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/recursion-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.